Brief Communication
participants were followed up initially until the completion of their course of oral antibiotic therapy. Further, each patient was reviewed by the end of every 3 months for 1 year. Commonly employed antibiotics included meropenem or ceftazidime as intensive treatment for 2 weeks followed by cotrimoxazole or doxycycline for 12 weeks as eradication therapy (http://www.cdc.gov/melioidosis/treatment).
During the follow-up visits, patients were examined thoroughly for clinical and microbiological cure of the disease. Recurrent disease was defined as clinical features of melioidosis in association with one or more cultures positive for B. pseudomallei in a patient with a history of one or more previous episodes. [5] Amongst patients with recurrence of clinical signs and/or symptoms of the melioidosis, relevant clinical specimens were subjected to microbiological culture and polymerase chain reaction (PCR) targeting the TTS1 gene specific for B. pseudomallei as described previously. [6] This included patients who had recurrent symptoms after completing treatment, together with patients who were undergoing oral therapy. [5] Paired isolates (from initial and recurrence) obtained from patients with recurrent melioidosis were subjected to MLST as described previously. [7] Alleles at each of the seven loci were assigned, and the allelic profile was used to define the sequence type (ST) using the B. pseudomallei MLST website (http://pubmlst.org/bpseudomallei/). Further, minimum inhibitory concentrations for ceftazidime, meropenem, doxycycline and cotrimoxazole amongst the paired isolates were tested as per the CLSI guidelines (M45-A2). Isolates from the same patient with different ST were defined as reinfection while those with similar ST were categorised as relapse.
Results
Thirty-eight patients with microbiological culture-confirmed melioidosis were recruited during the study duration. The mean age of study population was 52.73 ± 14.31 years. Majority of them were males (n = 30, 78.9%). Eight (21%) of the study population were agriculturists by profession. Twenty-seven (71%) patients were diabetic and 7 (18.4%) of them had chronic kidney disease. Of the 38 patients, 20 (52.6%) presented with systemic form (bacteraemia) of the disease followed by localised and pulmonary forms in 13 (35.1%) and 4 (10.8%) patients, respectively. Detailed description of baseline demographics, clinical signs and symptoms, comorbidities, course of treatment and the clinical outcomes amongst the study population is enlisted in Table 1 .
Amongst 37 cases, 30 (81%) received the complete course of pathogen-specific antibiotic therapy, 4 (10.8%) were discharged against medical advice before the initiation of specific antibiotic therapy and 3 (8.1%) patients expired before the diagnosis was made. Amongst the 30 patients who received complete antimicrobial therapy, ceftazidime (n = 15, 50%) followed by meropenem (n = 13, 43.3%) was commonly used for the initial intensive phase therapy and cotrimoxazole (n = 14, 46.6%) followed by amoxicillin-clavulanic acid (n = 10, 33.3%) for eradication-phase therapy. Amongst the 30 patients with follow-up data available, 5 (16.6%) patients presented with clinical signs and symptoms suggestive of recurrent melioidosis. However, microbiological culture positivity of B. pseudomallei which is confirmatory for the diagnosis of recurrent melioidosis was observed amongst 3 (10%) patients and the other 2 patients were negative for B. pseudomallei both by culture and PCR. At all instances, throat swab and urine samples were collected and confirmed by B. pseudomallei specific culture and PCR. Based on the MLST, two of the three patients were found to be infected with new ST during the recurrence of the disease, suggesting a reinfection. Details regarding the clinical features, treatment and STs amongst patients with recurrent melioidosis are mentioned in Table 2 .
dIscussIon
Recurrence of symptoms after effective treatment of melioidosis is a vexing clinical problem. Relapse with the same strain and reinfection with a new strain have both been documented with recurrent form of the disease. Understanding the cause of recurrence is vital for clinical management. In such cases, molecular typing technique such as MLST can act as an important tool to differentiate between relapse and reinfection. Based on the comparison of the seven housekeeping genes, consecutive isolates can be designated as similar or different strains. However, because of high rates of homologous recombination in B. pseudomallei, MLST might be a less reliable option to establish a genotypic relationship amongst its STs. The possibility of a mutation in one or few housekeeping genes, although remote, would be sequenced to generate a novel ST. Thus, what might have actually been a case of relapse with B. pseudomallei may be misinterpreted as a reinfection. [8] Conversely, it could also be possible that a patient has been reinfected with a B. pseudomallei strain with ST identical to that of the primary isolate; in such instances, this might erroneously be labelled as relapse. In such a scenario, more advanced technology such as whole genome sequencing might be required.
Appropriate antibiotic therapy is an established factor in determining disease outcome of melioidosis. Besides administration of inappropriate initial intensive treatment, relapses have also been attributed to poor compliance during the eradication phase of therapy. The use of amoxicillin-clavulanic acid monotherapy for eradication has been attributed to higher incidence of relapse. [9] In the present study, 33% (n = 10) cases received amoxicillin-clavulanic acid as oral regimens, but relapse was witnessed amongst none of the cases.
On the contrary, reinfection necessitates aggressive prevention strategies amongst cases. Reinfection could indicate an exposure to a new strain from the environment which could be attributed to higher burden of the pathogen in the environs of the individuals affected. Unrecognised host factors could also be contributory to reinfection with B. pseudomallei.
A few instances were individual infection seem to have occurred due to concurrent infection from different B. pseudomallei strains at different sites. [9] The occurrence of a new strain from the same individual might attribute to the presence of different strains in the ecosystem. Hence, an individual might get infected with more than one strain in the initial episode and what might look like reinfection could be relapse.
One of the limitations of this study was access to small population of cases diagnosed with melioidosis for follow-up. Despite this, our results show considerable concordance to rates of recurrence reported earlier from other parts of the world. [3, 9] In our study population, we did not witness a major change in the antibiogram between the isolates obtained at two different instances. This suggests that antibiogram may not be conclusive in distinguishing isolates from relapse or reinfection. This study defines the role of molecular typing which can be an important tool in differentiating cases of relapse from reinfection. From a clinical standpoint, this study emphasises not only the importance of maintaining a high index of suspicion of recurrence amongst melioidosis patients presenting repeatedly with similar symptoms but also the significance of regular comprehensive follow-up of these patients, even months after completing the eradication therapy. 
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